detection of e-6 antigen (human papilloma virus-16) and h11b2c2 antigen (habp) in cervical cancer tissues

background: cervical cancer is one of the most common types of women’s reproductive cancers. a major risk factor for cervical cancer is exposure to a group of common sexually transmitted viruses called human papillomavirus  (hpv). the over expression of hpv 16 i.e., e6 antigen in the tumors of suspected cervical cancer tissues. however e-6 antigen has hyaluronan binding protein site. methods: the procedure carried out by using 15 benign and 50 different grades of cervical cancer tissue samples to study the expression of  hpv 16 i.e., e6 antigen and h11 antigen(habp) by biochemical method. results: the hpv 16 i.e., 18kd is expressing along with hyaluronic acid binding proteins 57kd and 92kd. this shows that e-6 antigen itself reacting with hyaluronic acid binding sites. conclusion: the h11 antigen (habp) reacted with anti e-6 protein indicating hyaluronic acid binding protein 57kd and 92 kd is reacting with anti e6 antibody. these results showed a partial homology between e6 and h11 antigen (habp). thus the homology between the two proteins in tumor cells is an important parameter and a clinical diagnostic marker for progressive human tumors. key words: human papilloma virus (hpv); h11 antigen (habp); cervical cancer tissue; e-6 antigen references 1. de villiers, e. m., l. gissmann, h. zur hausen. molecular cloning of viral dna from human genital warts. j. virol. 1981; 40:932-5. 2. gissmann, l., h. zur hausen. partial characterization of viral dna from human genital warts (condylomata acuminata). int. j. cancer, 1980; 25:605-9. 3. zur hausen, h. papillomaviruses and cancer: from basic studies to clinical application. nature, 2000; 2:342-50. 4. bosch manos n, munoz m, sherman a, jansen j, peto m, schiffman h, et al. prevalence of human papillomavirus in cervical cancer: a worldwide perspective. j. natl. cancer inst. 1995; 87:796-802. 5. walboomers jm, jacobs mv, manos mm, bosch fx, kummer ja, shah kv, et al. human papillomavirus is a necessary cause of invasive cervical cancer worldwide. j pathol.1999; 189: 12-9. 6. hillemanns p, kimmig r, huttemann u. screening for cervical neoplasia by self-assessment for human papillomavirus dna. lancet 1999, 4; 354(9194):1970. 7. wright tc, denny l and kuhn l,. hpv dna testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. jama, 2000; 283:81-6. 8. scheffner m, werness ba, huibregtse j m, levine aj and howley pm. the e6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. cell. 1990; 63: 1129-36. 9. schiffman m., herrero r,hildesheim a, sherman m. e, bratti m., wacholder s, et al. hpv dna testing in cervical cancer screening: results from women in a high-risk province of costa rica. jama. 2000; 283: 87-93. 10. dyson n., guida p, münger k, harlow e. homologous sequences in adenovirus e1a and human papillomavirus e7 proteins mediate interaction with the same set of cellular proteins. j. virol.1992; 66:6893-6902. 11. jiang m, milner j. selective silencing of viral gene expression in hpv-positive human cervical carcinoma cells treated with sirna, a primer of rna interference. oncogene, 2002; 21:6041-8. 12. butz k, ristriani t, hengstermann a, denk c, scheffner m, hoppe-seyler f. sirna targeting of the viral e6 oncogene efficiently kills human papillomavirus-positive cancer cells. oncogene. 2003; 22:5938-45. 13. yoshinouchi m, yamada t, kizaki m, fen j, koseki t, ikeda y,et al. in vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by e6 sirna. mol ther.2003; 8: 762-8. 14. de roda husman am, walboomers jm, van den brule aj. the use of general primers gp5 and gp6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by pcr. j gen virol.1995; 76: 1057-62. 15. vassilakos p, griffin s, megevand e, campana a. cyto rich liquid-based cervical cytologic test. screening results in a routine cytopathology service. acta cytol. 1998; 42:198-202. 16. draganov, p, todorov s, todorov i, karchev t, kalvatchev z. identification of hpv dna in patients with juvenile-onset recurrent respiratory papillomatosis using sybr green real-time pcr. int. j. pediatr. otorhinolaryngol. 2006; 70: 469-73. 17. del mistro a, salamanca hf, treyisan r, bertorelle r, parenti a, bonoldi e, et al. human papillomavirus typing of invasive cervical cancers in italy. infect agent cancer. 2006; 27:1-9. 18. sin. j.i human papillomavirus vaccines for the treatment of cervical cancer. experts rev vaccines .2006; 5: 783-92. 19. gok m, coupe vm, berkhof j, verheijen rh, helmerhorst tj, hogewoning cj, et al. hpv16 and increased risk of recurrence after treatmentforcin. gynecol oncol. 2007; 104: 273-5. 20. linn yy., alphs. h., hung cf, roden rb, wu tc. vaccines against human papillomavirus. front biosci.2007; 12: 246-64. 21. vassilakos p, griffin s, megevand e, campana a. cytorich liquid-based cervical cytologic test. screening results in a routine cytopathology service. acta cytol. 1998; 42:198-202. 22. banerjee s.d, toole bp .the determinants of migrating with a pre-arranged job and of the initial duration of urban unemployment: an analysis based on indian data on rural-to-urban migrants.j dev econ. 1991; 36:337-51. 23. laemmli uk. cleavage of structural proteins during the assembly of the head of bacteriophaget4.nature. 1970; 227:680-5. 24. oh st, longworth ms, laimins la. roles of the e6 and e7 proteins in the life cycle of low-risk human papillomavirus type 11. j. virol. 2004; 78: 2620-6.